NEW YORK, June 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Liver Cancer Drugs industry
http://www.reportlinker.com/p0197204/Global-Liver-Cancer-Drugs-industry.html
This report analyzes the Global market for Liver Cancer Drugs in US$ Million. Annual estimates and forecasts are provided for the period 2007 through 2015. The report profiles 40 companies including 4SC AG, Actavis Group, Inc., Alnylam Pharmaceuticals, Inc., ArQule, Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Celsion Corp, Eli Lilly & Company, ImClone Systems Inc., F. Hoffmann–La Roche Ltd., Jennerex Biotherapeutics, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
LIVER CANCER DRUGS MCP-6297
A GLOBAL MARKET REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW & DYNAMICS II-1
Current Scenario and Outlook II-1
Asians Lead in Liver Cancer Prevalence and Incidence II-1
Table 1: Incidence and Mortality of Liver Cancer in Select
Countries: 2007 (includes corresponding Graph/Chart) II-2
Disparity in Epidemiology and Etiology Of Liver Cancer II-2
Liver Cancer Incidence Rising in the US II-3
HCC Incidence Declines in Japan II-3
Conventional Therapies Plagued with Lower Penetration II-4
Therapies and Eligible Patient Population II-5
Major Target Population Exists for Targeted Therapies II-5
Nexavar - The Only Approved Targeted Therapy in Liver Cancer II-5
Table 2: Global Nexavar Sales (2007-2015) (in US$ Million)
(includes corresponding Graph/Chart) II-6
Japanese Approval for Nexavar® in 2009 II-6
Nexavar Proves Efficacy in Asian Patients II-7
Nexavar Ongoing Clinical Trials II-7
Nexavar Being Evaluated As Adjuvant Therapy II-7
Development of Nexavar Plus Tarceva Therapy Underway II-7
Liver Cancer Treatment to Boost Nexavar's Revenues II-8
ThermoDox Likely to Enter Market in 2011 II-8
Table 3: Worldwide ThermoDox Sales: 2011-2015 (includes
corresponding Graph/Chart) II-9
Liver Cancer Therapy - Attracting Increasing Research Efforts II-9
Combination Drugs to Make an Impact II-10
Pipeline Drugs in Liver Cancer Treatment - A Snapshot II-10
Select Pipeline Drugs in Phase III Clinical Trials for Liver
Cancer Treatment II-10
Select Pipeline Drugs in Phase II Clinical Trials for Liver
Cancer Treatment II-11
Select Pipeline Drugs in Other Clinical Trial Stages for
Liver Cancer Treatment II-12
Overview of Select Drugs In Pipeline II-12
Sutent® (Pfizer) II-12
ThermoDox + RFA (Celsion Corp.) II-12
Sorafenib + TACE (Bayer) II-13
Sorafenib + Tegafur/Uracil II-13
Muparfostat (Formerly PI-88) (Progen Pharmaceuticals/ Global
TransBiotech) II-13
Avastin + Tarceva (Roche/Genentech) II-14
NX-1207 (Nymox Pharmaceutical Corp.) II-14
ALN-VSP (Alnylam Pharmaceuticals, Inc.) II-15
AV-951 (Aveo Pharmaceuticals) II-15
JX-594 (Jennerex) II-15
Afinitor/RAD001 (Novartis) II-16
4SC-201 (4SC) II-16
CTCE-9908 (Chemokine Therapeutics) II-17
ARQ 197 (ArQule, Inc.) II-17
2. DISEASE OVERVIEW II-18
Liver - A Vital Organ II-18
Functions of the Liver II-18
Overview of Liver Cancer II-18
Benign Liver Tumors II-19
Types of Benign Liver Tumors II-19
Hemangiomas II-19
Hepatic Adenomas II-19
Focal Nodular Hyperplasia II-19
Malignant Liver Tumors II-20
Types of Liver Cancer II-20
Hepatocellular Carcinoma (HCC) II-20
Cholangiocarcinomas II-20
Hepatoblastoma II-20
Hemangiosarcomas and Angiosarcomas II-20
Hepatoblastoma II-21
Secondary Liver Cancer or Metastatic Cancer II-21
Risk Factors II-21
Symptoms of Liver Cancer II-21
Tests for Detection of Liver Cancer II-22
Diagnosis of Liver Cancer II-23
Blood Tests II-23
Imaging Studies II-24
Ultrasound II-24
Computed Tomography II-24
Magnetic Resource Imaging II-24
Angiography II-25
FDG-PET II-25
Biopsy II-25
Prognosis of Liver Cancer II-25
Treatment Of Liver Cancer II-27
Targeted Therapy II-27
Working of Targeted Cancer Therapies II-27
Development of Targeted Therapies II-27
Effect of Targeted Therapies on the Treatment of Cancer II-28
Chemotherapy II-28
Surgery II-28
Side Effects and Risks Associated with Surgery II-29
Cryosurgery II-29
Benefits of Cryosurgery II-29
Limitations of Cryosurgery II-30
Liver Transplant II-30
Side effects and Risks Associated with Liver Transplantation II-30
Tumor Embolization and Ablation II-30
Radiation Therapy II-31
Side-effects Associated with Radiation Therapy II-31
Radiofrequency Ablation II-31
Hepatic Artery Chemoembolization II-31
A Focus on Hepatocellular Carcinoma II-32
Epidemiology II-32
Pathogenesis II-32
Pathology II-33
Prognosis and Staging II-33
Treatment II-33
Treatment Follow-up II-35
3. NEXAVAR'S APPROVALS IN REGIONAL MARKETS II-36
Bayer Secures Japanese Approval for Nexavar® II-36
Bayer Obtains Approval for Nexavar in China II-36
Bayer Obtains Approval for Marketing Nexavar® in Singapore II-36
Bayer Receives Health Canada's Approval for Nexavar II-36
Bayer Obtains FDA Approval for Nexavar in Treating Liver Cancer II-37
Bayer Receives EU Clearance for Marketing Nexavar II-37
4. RECENT INDUSTRY ACTIVITY II-38
NICE Refuses to Take Nexavar on National Health Service (NHS) II-38
Delcath's Doxorubicin Obtains Orphan-Drug Designation from FDA II-38
CACMS Obtains Clearance for Traditional Chinese Medicine for
Liver Cancer II-38
Curetech Obtains FDA Approval to Commence Trial on CT-011 II-38
Bayer Mulls Over Legal Recourse to Avert Nexavar' Generic in
India II-39
Jennerex Generates Funds for Developing JX-594 II-39
Celsion to Extend ThermoDox Phase III Trial to Japan II-39
Bayer Commences Phase III trials on Nexavar and Tarceva
Combination Therapy II-40
Tiandiren Pharma Begins Construction of Biotech Park II-40
Can-Fite to Commence Phase I/II Trial of CF102 II-40
Celsion's ThermoDox Obtains Orphan Drug Designation from FDA II-40
Alnylam Obtains FDA Clearance to Commence Phase I Trial on
ALN-VSP II-41
ArQule Enrolls Patients for Phase II Study with ARQ 197 in
Hepatocellular Carcinoma II-41
PharmaSynth Licenses Muparfostat to Global TransBiotech II-42
Bayer-Onyx Commences Clinical Trials on Nexavar as Adjuvant
Therapy II-42
Protherics Begins Phase II Clinical Trial on Prolarix II-42
Chemokine Obtains Hong Kong DoH Clearance on CTCE-9908 II-42
AstraZeneca Forges New Alliance for Anti-Cancer Compounds II-43
BioAlliance Annuls Trials on Transdrug® for Liver Cancer
Treatment II-43
Chemokine Obtains Health Canada Approval to Start CTCE-9908
Phase II Trial II-43
Progen Pharmaceuticals Spins-Off its Manufacturing Business II-44
Metabasis Obtains EMEA Orphan Drug Designation for Liver
Cancer Drug II-44
Metabasis Obtains FDA Orphan Drug Designation for Liver Cancer
Drug II-44
5. FOCUS ON SELECT GLOBAL PLAYERS II-46
4SC AG (Germany) II-46
Actavis Group, Inc. (USA) II-46
Alnylam Pharmaceuticals, Inc. (USA) II-47
ArQule, Inc. (USA) II-47
Bayer Schering Pharma AG (Germany) II-48
Bristol-Myers Squibb Company (US) II-49
Celsion Corp. (USA) II-49
Eli Lilly & Company (US) II-50
ImClone Systems Inc. II-50
F. Hoffmann-La Roche Ltd. (Switzerland) II-51
Jennerex Biotherapeutics, Inc. (USA) II-51
Onyx Pharmaceuticals, Inc. (USA) II-52
Pfizer Inc. (USA) II-52
Progen Pharmaceuticals Ltd. (Australia) II-53
Teva Pharmaceutical Industries Ltd. (Israel) II-53
6. GLOBAL MARKET PERSPECTIVE II-54
Table 4: World Recent Past, Current & Future Analysis for
Liver Cancer Drugs Market Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) II-54
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 50 (including Divisions/Subsidiaries - 54)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 28
Canada 3
Japan 3
Europe 12
France 2
Germany 5
The United Kingdom 3
Rest of Europe 2
Asia-Pacific (Excluding Japan) 5
Middle East 3
------------------------------------------
To order this report:
Drug and Medication Industry: Global Liver Cancer Drugs industry
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article